DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype

Haemophilia

Volumn 18, Issue 1, 2012, Pages 50-55

  Seary, M E ^a   Feldman, D ^a   Carcao, M D ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Desmopressin; Genetics; Haemophilia A; Paediatrics

Indexed keywords

BLOOD CLOTTING FACTOR 8C; DESMOPRESSIN;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; DISEASE SEVERITY; GENETIC ASSOCIATION; GENOTYPE; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HEMOSTATICS; HUMANS; INFANT; MALE; MUTATION;

EID: 84355166758     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02572.x     Document Type: Article

References (24)

1. Mannucci PM, Åberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
2. Lethagen S. Desmopressin - a haemostatic drug: state of the art review. Eur J Anaesthesiol Suppl 1997; 14: 1-9.
3. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatric Blood Cancer 2006; 46: 547-53.
4. Mannucci PM, Pareti FI, Holmberg L, Nilsson IM, Ruggeri ZM. Studies on the prolonged bleeding time in von Willebrand disease. J Lab Clin Med 1976; 88: 662-71.
5. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-36.
6. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica 1999; 84: 891-6.
7. Villar A, Jimenez-Yuste V, Quintana M, Hernandez-Navarro F. The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents. Haemophilia 2002; 8: 189-93.
8. Manucci PM. Desmopressin (DDAVP) and factor VIII: the tale as viewed from Milan (and Malmö). J Thromb Haemost 2003; 1: 623-4.
9. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 11-14.
10. Francis JD, Leary T, Nibilett DJ. Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline hemophilia. Acta Anaesthesiol Scand 1999; 43: 870-3.
11. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
12. Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children. J Pediatr Hematol Oncol 2005; 27: 330-2.
13. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 2002; 117: 947-51.
14. Poon M-C, Lillicrap DP, Israels SJ, the Association of Haemophilia Clinic Directors of Canada. Haemophilia and von Willebrand disease consensus statements on current management. 1. Diagnosis, comprehensive care concept, and assessment. Can Med Assoc J 1995; 153: 19-25.
15. Cattaneo M. Review of clinical experience of desmopressin in patients with congenital and acquired bleeding disorders. Eur J Anaesthesiol 1997; 14(Suppl): 10-14.
16. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia 2008; 14(Suppl. 1): 15-20.
17. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20years. Blood 1997; 90: 2515-21.
18. Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109: 865-9.
19. Kavakli K, Hüseyinov A, Coker I, Aydinok Y, Nisli G. Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease. Haemophilia 2001; 7: 482-9.
20. De La Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
21. Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986; 8: 19-45.
22. Rushton HG, Belman AB, Zaontz MR, Skoog SJ, Sihelnik S. The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis. J Urol 1996; 156: 651-5.
23. Ervin MG, Ross MG, Leake RD, Fisher DA. V1- and V2-receptor contributions to ovine fetal renal and cardiovascular responses to vasopressin. Am J Physiol 1992; 262: 636-43.
24. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000.